Novartis Pharmaceuticals UK Ltd

Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR
Telephone: +44 (0)1276 692 255
Fax: +44 (0)1276 698 449
Medical Information Direct Line: +44 (0)1276 698 370
Medical Information e-mail: medinfo.uk@novartis.com
Customer Care direct line: +44 (0)845 741 9442

Patient Information Leaflet last updated on the eMC: 25/03/2009
PIL Lescol (fluvastatin sodium) 20 mg and 40 mg capsules

On 3 November 2009, the MHRA issued additional safety information for this product. A Europe-wide review of clinical trial data, adverse drug reaction reports and published literature on statins has concluded that any of the following adverse reactions may be associated with statin use: sleep disturbances, memory loss, sexual dysfunction, depression and interstitial lung disease (leading to breathing problems). Product information for all statins will be updated with warnings on all of these side effects.

Further information can be found on the MHRA website.


The patient information leaflet you have selected is in PDF format.

View Patient Information Leaflet (0.73MB)

Can't read the PDF? Visit adobe.com and download the Adobe Acrobat Reader.


More information about this product

Link to this document from your website: http://emc.medicines.org.uk/medicine/3781/XPIL/Lescol (fluvastatin sodium) 20 mg and 40 mg capsules/

Active Ingredients/Generics

 
   fluvastatin sodium


© 2009 Datapharm Communications Ltd

Go to www.medicines.org.uk